Logo

American Heart Association

  13
  0


Final ID: TMP106

Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: Insights from the All of Us Research Program

Abstract Body: Background: Adverse pregnancy outcomes (APOs) have been linked to increased cardiovascular risks, but longitudinal studies in diverse U.S. populations are limited.

Objective: To investigate the association between APOs and the timing and incidence of cardiovascular events in a large, diverse cohort.

Methods: We analyzed longitudinal data from the All of Us Research Program focusing on adverse pregnancy outcomes (APOs) as the exposure. The primary outcome was a composite of cardiovascular events including ischemic stroke, intracerebral hemorrhage (ICH), heart failure (HF), and myocardial infarction (MI). We assessed the incidence and age at onset of these cardiovascular events, comparing women with and without APOs. Adjusted hazard ratios (HRs) were estimated using Cox multiple regression models to analyze the impact of APOs on the risk of cardiovascular events. We used linear regression to examine the relationship between adverse pregnancy outcomes (APOs) and age at cardiovascular events, including interaction and stratified analyses by race/ethnicity.

Results: In All of Us, out of a total of 414,570 participants, we found 10,602 parous women, mean age at birth was 29.63 (6.59). Five thousand, six hundred twenty (54%) had at least one APO, including 1,089 (10.5%) who experienced preeclampsia-eclampsia, 1,044 (10.0%) gestational hypertension, 1,146 (11.0%) gestational diabetes, 637 (6.1%) fetal growth restriction, 612 (5.9%) experienced placental abruption, and 1,092 (10.5%) had preterm births. Women with APOs had a significantly increased risk of composite adverse cardiovascular outcomes (adjusted HR: 1.45; 95%CI:11.13-1.85) and specific events such as ischemic stroke (adjusted HR: 1.51; 95%CI:1.03-2.22) and heart failure (adjusted HR: 1.34; 95%CI:1.03-1.89). Additionally, APOs were linked to a younger age at cardiovascular events, with significant variations by race/ethnicity(interaction p<0.05). Black participants with APOs had a younger age at cardiovascular outcome (β -3.99; p<0.001), as did Hispanic participants (β -3.31; p=0.03). This association was not significant in White participants after adjustment.

Conclusions: APOs are associated with an increased risk and earlier onset of cardiovascular events among a representative and diverse cohort of American parous women.
  • Renedo, Daniela  ( Yale School of Medicine , New Haven , Connecticut , United States )
  • Schwamm, Lee  ( Yale School of Medicine , New Haven , Connecticut , United States )
  • Kamel, Hooman  ( Yale School of Medicine , New Haven , Connecticut , United States )
  • Matouk, Charles  ( Yale University , New Haven , Connecticut , United States )
  • Tal, Reshef  ( Yale School of Medicine , New Haven , Connecticut , United States )
  • Sheth, Kevin  ( YALE UNIVERSITY SCHOOL OF MEDICINE , New Haven , Connecticut , United States )
  • Falcone, Guido  ( YALE UNIVERSITY SCHOOL OF MEDICINE , New Haven , Connecticut , United States )
  • Chaves-rivera, Maria Natalia  ( Yale School of Medicine , New Haven , Connecticut , United States )
  • Rivier, Cyprien  ( Yale University , New Haven , Connecticut , United States )
  • Koo, Andrew  ( Yale School of Medicine , New Haven , Connecticut , United States )
  • Clocchiatti-tuozzo, Santiago  ( Yale University , New Haven , Connecticut , United States )
  • Huo, Shufan  ( Yale University , New Haven , Connecticut , United States )
  • Sujijantarat, Nanthiya  ( Yale University , New Haven , Connecticut , United States )
  • Torres Lopez, Victor  ( Yale University , New Haven , Connecticut , United States )
  • Hebert, Ryan  ( Yale School of Medicine , New Haven , Connecticut , United States )
  • Author Disclosures:
    Daniela Renedo: DO NOT have relevant financial relationships | Lee Schwamm: DO have relevant financial relationships ; Consultant:genentech:Active (exists now) ; Advisor:Penumbra:Past (completed) ; Consultant:medtronic:Active (exists now) | Hooman Kamel: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Financial disclosures for Hooman Kamel: a PI role in the ARCADIA trial, which received in-kind study drug from the BMS-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics; a Deputy Editor role for JAMA Neurology; clinical trial steering/executive committee roles for the STROKE-AF (Medtronic), LIBREXIA-AF (Janssen), and LAAOS-4 (Boston Scientific) trials; consulting or endpoint adjudication committee roles for AbbVie, AstraZeneca, Boehringer Ingelheim, and Novo Nordisk; and household ownership interests in TETMedical, Spectrum Plastics Group, and Ascential Technologies.:Active (exists now) | Charles Matouk: DO have relevant financial relationships ; Consultant:Penumbra:Active (exists now) ; Consultant:Navigantis:Active (exists now) ; Consultant:Hybernia:Active (exists now) ; Consultant:Microvention:Active (exists now) ; Consultant:Silk Road Medical:Active (exists now) | Reshef Tal: DO NOT have relevant financial relationships | Kevin Sheth: DO NOT have relevant financial relationships | Guido Falcone: DO NOT have relevant financial relationships | Maria Natalia Chaves-Rivera: No Answer | Cyprien Rivier: DO NOT have relevant financial relationships | Andrew Koo: DO NOT have relevant financial relationships | Santiago Clocchiatti-Tuozzo: DO NOT have relevant financial relationships | Shufan Huo: DO NOT have relevant financial relationships | Nanthiya Sujijantarat: DO NOT have relevant financial relationships | Victor Torres Lopez: DO NOT have relevant financial relationships | Ryan Hebert: DO NOT have relevant financial relationships
Meeting Info:
Session Info:

Risk Factors and Prevention Moderated Poster Tour II

Thursday, 02/06/2025 , 06:00PM - 07:00PM

Moderated Poster Abstract Session

More abstracts on this topic:
Age-Varying Implications of Recalibration of Cardiovascular Disease Risk Prediction in a New England-Based Healthcare System

Cho So Mi, Natarajan Pradeep, Rivera Rachel, Koyama Satoshi, Kim Min Seo, Honigberg Michael, Bhattacharya Romit, Paruchuri Kaavya, Allen Norrina, Hornsby Whitney

A combined approach of cardiac magnetic resonance and CardioMEMS to assess right ventricular dysfunction during exercise in HFpEF-PH

Bekhuis Youri, Bogaert Jan, La Gerche Andre, Claessen Guido, Janssens Stefan, Droogne Walter, Rosseel Thomas, Barrios Leticia, Verwerft Jan, Timmermans Philippe, Trenson Sander, Dresselaers Tom

More abstracts from these authors:
Polygenic Resistance to Vascular Risk Factor Control in Stroke Survivors

Huo Shufan, Falcone Guido, Rivier Cyprien, Clocchiatti-tuozzo Santiago, Renedo Daniela, Torres Lopez Victor, Sunmonu N. Abimbola, Petersen Nils, De Havenon Adam, Sheth Kevin

Integrated Genomic and Proteomic Profiling Support Cathepsin-B as a Drug Repurposing Target in Cerebral Small Vessel Disease

Rivier Cyprien, Falcone Guido, Huo Shufan, Clocchiatti-tuozzo Santiago, Renedo Daniela, Sharma Richa, Payabvash Sam, Sansing Lauren, Rangaraju Srikant, Sheth Kevin

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.


   Rate this abstract  (Maximum characters: 500)